Posts tagged Master Protocols Guidance.
Blogs
6 minute read
On September 28, 2018, the U.S. Food and Drug Administration (FDA) released two draft guidances for industry. The purpose, according to FDA Commissioner Scott Gottlieb, M.D., is to modernize the approach to clinical trial design in efforts to (1) make clinical trials more efficient while maintaining patient safety and (2) increase the amount of information concerning product safety and benefits. The two draft guidances are entitled: “Master Protocols – Efficient Clinical Trial Design Strategies to Expedite Development of Cancer Drugs and Biologics” and “Adaptive ...
Blog Editors
Recent Updates
- Plunging Over the Telehealth Cliff: Now What?
- FTC Backs Off Non-Compete Ban, Warns Health Care Employers - Employment Law This Week Video
- HHS, FDA Target Direct-to-Consumer Drug Advertising: A Paradigm Shift in Patient-Focused Communications
- Texas Court Strikes Down CMS’s RADV Rule – CMS’s Treatment of Actuarial Equivalence and the FFS Adjustor Does Matter, After All
- A Step Closer to the Proposed End of the Self-Affirmed GRAS Pathway